Roth Capital initiated coverage of ARS Pharmaceuticals (SPRY) with a Buy rating and $40 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- Short Report: C3.AI short positioning at 2025-high
- Ars Pharmaceuticals Reports Strong Q2 Growth and Global Expansion
- ARS Pharmaceuticals Faces Patent Challenge from Lupin
- ARS Pharmaceuticals: Strong Market Position and Growth Potential Justify Buy Rating
- ARS Pharmaceuticals Reports Strong Growth for neffy